Compare REGN & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | SNY |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3B | 95.7B |
| IPO Year | 1995 | 2001 |
| Metric | REGN | SNY |
|---|---|---|
| Price | $919.82 | $46.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 11 |
| Target Price | ★ $991.00 | $54.92 |
| AVG Volume (30 Days) | 869.8K | ★ 4.2M |
| Earning Date | 10-30-2026 | 10-30-2026 |
| Dividend Yield | 0.41% | ★ 5.25% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 37.37 | N/A |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $31.18 | $3.97 |
| Revenue Next Year | $7.19 | $6.77 |
| P/E Ratio | $24.71 | ★ $6.14 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $591.52 | $39.07 |
| 52 Week High | $991.73 | $50.61 |
| Indicator | REGN | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 57.41 | 57.70 |
| Support Level | $735.26 | $45.95 |
| Resistance Level | $986.64 | $48.57 |
| Average True Range (ATR) | 32.57 | 0.86 |
| MACD | -4.43 | -0.20 |
| Stochastic Oscillator | 32.58 | 40.49 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.